{"filing":{"accession_number":"0001091818-26-000084","cik":"0001310488","ticker":"BFNH","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"bfnh-06182026_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/bfnh-06182026_8k.htm"},"events":[{"id":11720,"run_id":10303,"accession_number":"0001091818-26-000084","anchor_item_number":"5.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Merle Ferguson sold 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000 on April 15, 2026, resulting in a change of control of the registrant.","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8377,"accession_number":"0001091818-26-000084","item_number":"5.01","item_title":"CHANGES IN CONTROL OF THE REGISTRANT","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a change of control transaction where Merle Ferguson sold 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000 on April 15, 2026. This constitutes a material acquisition/change of control event under Item 5.01, representing a fundamental shift in company ownership and control. The supplemental exhibits showing multiple director resignations further corroborate the material nature of this control change.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11721,"run_id":10303,"accession_number":"0001091818-26-000084","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Two Co-CEOs (Steven Gagnon and John LaViolette) and Vice-President Sasha Shapiro resigned on June 17, 2026, materially affecting the registrant's senior leadership structure.","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8378,"accession_number":"0001091818-26-000084","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of two Co-CEOs (Steven Gagnon and John LaViolette) and a Vice-President (Sasha Shapiro) on June 17, 2026. While the section also includes the appointment of Scott Mager as a director and Richard Kaiser as interim CEO, the principal and most salient disclosed action is the departure of senior executives, particularly the dual CEO resignations, which materially affects the registrant's leadership structure and would concern a reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11722,"run_id":10303,"accession_number":"0001091818-26-000084","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The company disclosed a fundamental shift in business operations from vitamin supplements to oil and gas exploration, representing a material strategic pivot in the registrant's business direction and risk profile.","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8379,"accession_number":"0001091818-26-000084","item_number":"8.01","item_title":"OTHER VOLUNRARY DISCLOSURE OF OTHER EVENTS","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a fundamental shift in business operations from vitamin supplements to oil and gas exploration, which is material to investors' assessment of the company's strategic direction and risk profile. While three resignation letters are attached as exhibits (Gagnon, Laviolette, Shapiro), the Item 8.01 disclosure centers on the business pivot rather than the departures themselves, making this a strategic business change that does not fit neatly into the exec_departure category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8377,"accession_number":"0001091818-26-000084","item_number":"5.01","item_title":"CHANGES IN CONTROL OF THE REGISTRANT","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The disclosure describes a change of control transaction where Merle Ferguson sold 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000 on April 15, 2026. This constitutes a material acquisition/change of control event under Item 5.01, representing a fundamental shift in company ownership and control. The supplemental exhibits showing multiple director resignations further corroborate the material nature of this control change.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18"},{"id":8378,"accession_number":"0001091818-26-000084","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the resignation of two Co-CEOs (Steven Gagnon and John LaViolette) and a Vice-President (Sasha Shapiro) on June 17, 2026. While the section also includes the appointment of Scott Mager as a director and Richard Kaiser as interim CEO, the principal and most salient disclosed action is the departure of senior executives, particularly the dual CEO resignations, which materially affects the registrant's leadership structure and would concern a reasonable investor.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18"},{"id":8379,"accession_number":"0001091818-26-000084","item_number":"8.01","item_title":"OTHER VOLUNRARY DISCLOSURE OF OTHER EVENTS","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a fundamental shift in business operations from vitamin supplements to oil and gas exploration, which is material to investors' assessment of the company's strategic direction and risk profile. While three resignation letters are attached as exhibits (Gagnon, Laviolette, Shapiro), the Item 8.01 disclosure centers on the business pivot rather than the departures themselves, making this a strategic business change that does not fit neatly into the exec_departure category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:29:16.203003+00:00","company_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","ticker":"BFNH","filing_date":"2026-06-18"}]}